Atomo Diagnostics Joins With Access Bio To Globalize HIV POC Testing
Executive Summary
Australian firm Atomo Diagnostics and US-based Access Bio have joined forces to expand point-of-care HIV testing into markets beyond their domestic borders. Under the agreement, Access Bio will add Atomo's all-in-one rapid HIV diagnostic test to its infectious disease portfolio and market it to the professional-use segment.
You may also be interested in...
Atomo Takes Rapid, All-In-One Diagnostic Device Platform To A&E Pregnancy Testing Market
Australian company Atomo Diagnostics has collaborated with French company, NG Biotech, to develop a next-generation rapid pregnancy test based on the former's integrated diagnostic device platform. The test is due to launch in Europe in April 2017.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.